These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 7075948)

  • 1. Osteoporosis in primary biliary cirrhosis: effects of 25-hydroxyvitamin D3 treatment.
    Matloff DS; Kaplan MM; Neer RM; Goldberg MJ; Bitman W; Wolfe HJ
    Gastroenterology; 1982 Jul; 83(1 Pt 1):97-102. PubMed ID: 7075948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone disease in primary biliary cirrhosis: reversal of osteomalacia with oral 25-hydroxyvitamin D.
    Reed JS; Meredith SC; Nemchausky BA; Rosenberg IH; Boyer JL
    Gastroenterology; 1980 Mar; 78(3):512-7. PubMed ID: 7351289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone disease in primary biliary cirrhosis: histologic features and response to 25-hydroxyvitamin D.
    Herlong HF; Recker RR; Maddrey WC
    Gastroenterology; 1982 Jul; 83(1 Pt 1):103-8. PubMed ID: 6978827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 25-Hydroxyvitamin D3 treatment of bone disease in primary biliary cirrhosis.
    Arnaud SB
    Gastroenterology; 1982 Jul; 83(1 Pt 1):137-40. PubMed ID: 7075937
    [No Abstract]   [Full Text] [Related]  

  • 5. Changes in bone histomorphometry and bone mineral during treatment of osteoporosis with 1 alpha-hydroxyvitamin D3 and calcium.
    Lindholm TS; Nilsson OS; Elmstedt E; Eriksson SA; Lindholm TC; Kyhle BR
    Acta Vitaminol Enzymol; 1981; 3(3):170-6. PubMed ID: 7347489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effect of nandrolone decanoate, 1 alpha-hydroxyvitamin D3 or intermittent calcium infusion therapy on bone mineral content, bone remodeling and fracture rate in symptomatic osteoporosis: a double-blind controlled study.
    Geusens P; Dequeker J
    Bone Miner; 1986 Sep; 1(4):347-57. PubMed ID: 3333018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of 25-hydroxyvitamin D3 on vitamin D metabolites in primary biliary cirrhosis.
    Kaplan MM; Goldberg MJ; Matloff DS; Neer RM; Goodman DB
    Gastroenterology; 1981 Oct; 81(4):681-5. PubMed ID: 6973499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors influencing the development of metabolic bone disease in primary biliary cirrhosis.
    Guañabens N; Parés A; Mariñoso L; Brancós MA; Piera C; Serrano S; Rivera F; Rodés J
    Am J Gastroenterol; 1990 Oct; 85(10):1356-62. PubMed ID: 2220729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone mineral content, cortical thickness and fracture rate in osteoporotic women after withdrawal of treatment with nandrolone decanoate, 1-alpha hydroxyvitamin D3, or intermittent calcium infusions.
    Geusens P; Dequeker J; Verstraeten A; Nijs J; Van Holsbeeck M
    Maturitas; 1986 Dec; 8(4):281-9. PubMed ID: 3574141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of osteomalacia associated with primary biliary cirrhosis with parenteral vitamin D2 or oral 25-hydroxyvitamin D3.
    Compston JE; Horton LW; Thompson RP
    Gut; 1979 Feb; 20(2):133-6. PubMed ID: 311747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic bone disease in primary biliary cirrhosis at presentation.
    Mitchison HC; Malcolm AJ; Bassendine MF; James OF
    Gastroenterology; 1988 Feb; 94(2):463-70. PubMed ID: 3335317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preventive treatment of osteoporosis with 1 alpha-hydroxyvitamin D3 and calcium. Evaluation of bone histomorphometry in osteoporotics and age matched controls.
    Lindholm TS; Nilsson OS; Widhe T; Elmsted E; Eriksson S
    Acta Vitaminol Enzymol; 1982; 4(1-2):179-84. PubMed ID: 7124565
    [No Abstract]   [Full Text] [Related]  

  • 13. 1alpha-hydroxyvitamin D2 is less toxic but not bone selective relative to 1alpha-hydroxyvitamin D3 in ovariectomized rats.
    Weber K; Goldberg M; Stangassinger M; Erben RG
    J Bone Miner Res; 2001 Apr; 16(4):639-51. PubMed ID: 11315991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteoporosis in chronic cholestatic liver disease.
    Stellon AJ; Davies A; Compston J; Williams R
    Q J Med; 1985 Nov; 57(223):783-90. PubMed ID: 2934760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic osteodystrophy in primary biliary cirrhosis: effects of medical treatment.
    Crippin JS; Jorgensen RA; Dickson ER; Lindor KD
    Am J Gastroenterol; 1994 Jan; 89(1):47-50. PubMed ID: 8273797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intestinal absorption of 25-hydroxyvitamin D and osteomalacia in primary biliary cirrhosis.
    Compston JE; Thompson RP
    Lancet; 1977 Apr; 1(8014):721-4. PubMed ID: 66519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interim report on treatment of osteoporotic patients with 1 alpha-hydroxyvitamin D3 and calcium.
    Lindholm TS; Sevastikoglou JA; Lindgren U
    Clin Orthop Relat Res; 1978 Sep; (135):232-40. PubMed ID: 709936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of osteoporosis of ageing with 1alpha-hydroxycholecalciferol.
    Lund B; Hjorth L; Kjaer I; Reimann I; Friis T; Andersen RB; Sorensen OH
    Lancet; 1975 Dec; 2(7946):1168-71. PubMed ID: 53656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone disease in primary biliary cirrhosis: increased bone resorption and turnover in the absence of osteoporosis or osteomalacia.
    Cuthbert JA; Pak CY; Zerwekh JE; Glass KD; Combes B
    Hepatology; 1984; 4(1):1-8. PubMed ID: 6693061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of 1 alpha-hydroxyvitamin D3 on osteoporosis induced by immobilization combined with ovariectomy in rats.
    Okumura H; Yamamuro T; Kasai R; Hayashi T; Tada K; Nishii Y
    Bone; 1987; 8(6):351-5. PubMed ID: 3449110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.